
FDA Approves Vutrisiran For Adult Patients With ATTR-CM
The FDA has approved vutrisiran (Amvuttra) for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adult patients to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart …